Biomarker Discovery and Validation
Current issues in precision medicine and companion diagnostics development
- Difficulties in predictive biomarker discovery
- Lack of high-quality and well controlled tumor samples
- Lack of sufficient drug response and genomic information of clinical samples
- Difficulties in biomarker validation
- Difficulties to repeat experiments and test hypothesis in clinical settings
- Long and costly process for validating biomarkers in clinical trials
Advantages of using PDX models for biomarker discovery and validation
- PDX models better resemble human cancer tissues than cancer cell line xenograft models in tumor heterogeneity and hierarchy
- Large number of PDX models provide better coverage of cancer complexity
- Simultaneous testing of multiple drugs and combinations
- Reproducibility and flexibility
- Convenient tissue collection for high sample quality and reliable analysis
- Quick data acquisition and significant cost reduction